Claims for Patent: 9,494,597

Summary for Patent: 9,494,597

Title:	Human control antibodies and uses therefor
Abstract:	The present invention provides novel, rationally designed human control antibodies for use in various in vivo and in vitro applications. The antibodies of the present invention have well characterized variable domains that have been designed to minimize or eliminate antigen binding without altering gross antibody structure. Using the antibodies of the present invention in various assays allows researchers to distinguish effects that result from specific antigen-antibody interactions from other, non-specific antibody effects.
Inventor(s):	Chang; Hsiu-Ching (Lexington, MA), Hsu; Yen-Ming (Lexington, MA), Lee; Jeng-Shin (Lincoln, MA)
Assignee:	AB BIOSCIENCES, INC. (Allston, MA)
Application Number:	14/384,893
Patent Claims:	1. An isolated antibody or antigen binding fragment thereof, comprising: an adalimumab reference antibody having a modification within a CDRL3 region that eliminates TNF-binding, wherein the CDRL3 is SEQ ID NO: 44. 2. An isolated antibody or antigen binding fragment comprising: an adalimumab reference antibody having a modification within a CDRL2 region that eliminates TNF-binding, wherein the CDRL2 is SEQ ID NO: 42. 3. An isolated antibody or antigen binding fragment thereof, comprising: an adalimumab reference antibody having a modification within a CDRL1 region that eliminates TNF-binding, wherein the CDRL1 is SEQ ID NO: 40. 4. The isolated antibody or antigen binding fragment of claim 1, further comprising a modification within a CDRH1 region, wherein the CDRH1 is SEQ ID NO: 33. 5. The isolated antibody or antigen binding fragment of claim 1, further comprising a modification within a CDRH2 region, wherein the CDRH2 is SEQ ID NO: 35. 6. The isolated antibody or antigen binding fragment of claim 1, further comprising a modification within a CDRH3 region, wherein the CDRH3 is SEQ ID NO: 37. 7. The isolated antibody or antigen binding fragment of claim 1, further comprising a modification within a CDRH3 region, wherein the CDRH3 is SEQ ID NO: 38. 8. The isolated antibody or antigen binding fragment of claim 3, further comprising a modification within a CDRH3 region, wherein the CDRH3 is SEQ ID NO: 38. 9. An isolated antibody or antigen binding fragment thereof, comprising: an adalimumab reference antibody having a modification that eliminates TNF-binding, the modification within a heavy chain variable region, wherein the heavy chain variable region has an amino acid sequence selected from the group consisting of SEQ ID NOs: 54-64. 10. An isolated antibody or antigen binding fragment thereof, comprising: an adalimumab reference antibody having a modification that eliminates TNF-binding, the modification within a light chain variable region, wherein the light chain variable region has an amino acid sequence selected from the group consisting of SEQ ID NOs: 66-72. 11. An isolated antibody or antigen binding fragment thereof comprising: an adalimumab reference antibody having modifications that eliminate TNF-binding, wherein the modifications comprise: a light chain CDR1 region having amino acid substitutions S48A and Y54A and a heavy chain CDR3 region having amino acid substitutions L121A and D128A. 12. An isolated antibody or antigen binding fragment, comprising: an adalimumab reference antibody having a modification in a light chain CDR3 region, the modification comprising substitutions Y113A and Y118A relative to the reference antibody. 13. The isolated antibody or antigen binding fragment of claim 12, further comprising a mutation in heavy chain CDR1 region, wherein the mutation comprises amino acid substitutions N50A and Y51A relative to the reference antibody. 14. The isolated antibody or antigen binding fragment of claim 12, further comprising a mutation in heavy chain CDR2 region, wherein the mutation comprises amino acid substitutions S74A, Y79A and S82A relative to the reference antibody. 15. The isolated antibody or antigen binding fragment of claim 12, further comprising a mutation in heavy chain CDR3 region, wherein the mutation comprises amino acid substitutions S119A, Y120A and Y129A relative to the reference antibody. 16. The isolated antibody or antigen binding fragment of claim 12, further comprising a heavy chain CDR3 region, wherein the mutation comprises amino acid substitutions L122A and D128A relative to the reference antibody.

Details for Patent 9,494,597

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002		2032-04-02
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	02/21/2008		2032-04-02
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	04/24/2013		2032-04-02